TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28974567

Group type: EXPERIMENTAL
Intervention: On-treatment mean systolic blood pressure (SBP)
Number of subjects: 28790

Group type: EXPERIMENTAL
Intervention: Visit-to-visit systolic blood pressure variability (SBP-CV)
Number of subjects: 28790

Group type: EXPERIMENTAL
Intervention: Combined use of on-treatment mean SBP and SBP-CV
Number of subjects: 28790
Study: 26288199

Group type: EXPERIMENTAL
Intervention: SFC (25/125 mcg) through BAI
Number of subjects: 150

Group type: COMPARATOR
Intervention: SFC (25/125 mcg) through pMDI
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: SFC (25/125 mcg) through BAI and pMDI
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: BAI device
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: SFC in both BAI and pMDI
Number of subjects: 150
Study: 23972966

Group type: EXPERIMENTAL
Intervention: Eplerenone 50mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21288053

Group type: EXPERIMENTAL
Intervention: Increased dose of current PPI treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esomeprazole (more effective acid inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard PPI treatment (control)
Number of subjects: 0
Study: 19776456

Group type: EXPERIMENTAL
Intervention: Soft home care services and an offer of social caretaking
Number of subjects: 2612

Group type: COMPARATOR
Intervention: Only soft home care
Number of subjects: 2612
Study: 16508577

Group type: EXPERIMENTAL
Intervention: Swimming
Number of subjects: 116

Group type: COMPARATOR
Intervention: Walking
Number of subjects: 116
Study: 15285457

Group type: EXPERIMENTAL
Intervention: Organ electrodermal diagnostics (OED)
Number of subjects: 200
Study: 11584993

Group type: EXPERIMENTAL
Intervention: Amphotericin B with or without flucytosine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azoles and other formulations of amphotericin B
Number of subjects: 0
Study: 9227167

Group type: EXPERIMENTAL
Intervention: Oral hydroxychloroquine (HCQ)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intramuscular gold
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 8115343

Group type: EXPERIMENTAL
Intervention: Pipeline condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saliva thiocyanate measure
Number of subjects: 0
Study: 3117402

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of adriamycin (20 mg/40 ml or 30 mg/30 ml)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of mitomycin C (20 mg/40 ml)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of thio-TEPA (30 mg/30 ml)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Noninstillation treatments with etretinate or tegafur
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Stage 1 or grade 2 disease treated with prophylactic instillation
Number of subjects: 130
Study: 31356704

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy for PTSD
Number of subjects: 90
Study: 29068297

Group type: EXPERIMENTAL
Intervention: Care-management approach (Group 1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional approach (Group 2)
Number of subjects: 10
Study: 25683060

Group type: EXPERIMENTAL
Intervention: Neurokinin B (NKB) administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle (placebo) infusion
Number of subjects: 10
Study: 23650890

Group type: EXPERIMENTAL
Intervention: Intervention programme for morphosyntactic skills
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 21460066

Group type: EXPERIMENTAL
Intervention: Cartilage Autograft Implantation System (CAIS)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Microfracture (MFX)
Number of subjects: 29
Study: 18641093

Group type: EXPERIMENTAL
Intervention: CT scan-guided bronchoscopy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional bronchoscopy
Number of subjects: 50
Study: 16920776

Group type: EXPERIMENTAL
Intervention: Intervention group (114 players)
Number of subjects: 723

Group type: COMPARATOR
Intervention: Control group (609 players)
Number of subjects: 723
Study: 12895165

Group type: EXPERIMENTAL
Intervention: Aspirin 50 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aspirin 80 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aspirin 162.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no coronary artery disease)
Number of subjects: 60
Study: 10718778

Group type: EXPERIMENTAL
Intervention: Sibrafiban
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ticlopidine/Aspirin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sibrafiban/Ticlopidine/Aspirin
Number of subjects: 38
Study: 8824104

Group type: EXPERIMENTAL
Intervention: Computer-based instruction
Number of subjects: 34

Group type: COMPARATOR
Intervention: Personal instruction (Control)
Number of subjects: 34
Study: 1467104

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 500
Study: 6748068

Group type: EXPERIMENTAL
Intervention: Postcard reminders
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Self-managed use of calendars with sticker reminders
Number of subjects: 189

Group type: COMPARATOR
Intervention: Non-cyclic women
Number of subjects: 189
Study: 31584222

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 35
Study: 30293295

Group type: EXPERIMENTAL
Intervention: 1 mg carboprost methylate suppository
Number of subjects: 1614
Study: 25642882

Group type: EXPERIMENTAL
Intervention: Warm plastic bag application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no warm bag application)
Number of subjects: 0
Study: 23782001

Group type: EXPERIMENTAL
Intervention: vitamins and minerals (vit&min) treatment (group A; N.274)
Number of subjects: 552

Group type: COMPARATOR
Intervention: calcium/vitamin D3 treatment (group B; N.278)
Number of subjects: 552
Study: 21832831

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with birch extract
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with birch extract
Number of subjects: 40
Study: 19737029

Group type: EXPERIMENTAL
Intervention: Cold conditions (ambient temperature: 5 +/- 1 degrees C, relative humidity 41% +/- 9%)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Room temperature conditions (ambient temperature: 21 +/- 1 degrees C, relative humidity 35% +/- 5%)
Number of subjects: 22
Study: 17576867

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg BID
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg BID
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30 mg BID
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 40 mg once daily
Number of subjects: 418

Group type: COMPARATOR
Intervention: Enoxaparin/vitamin K antagonist
Number of subjects: 418
Study: 14991935

Group type: COMPARATOR
Intervention: Omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g twice daily for 1 week (Group I)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g twice daily for 2 weeks (Group II)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Bismuth subsitrate 300 mg, tetracyline 500 mg, metronidazole 500 mg four times daily in addition to Omeprazole 20 mg twice daily (Group III)
Number of subjects: 164
Study: 11458720

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg b.w.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Midazolam (for treatment of severe agitation)
Number of subjects: 10
Study: 9715356

Group type: EXPERIMENTAL
Intervention: Cocaine-alcohol (4 doses of intranasal cocaine 1 mg/kg every 30 min with oral alcohol 1 g/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cocaine (4 doses of intranasal cocaine 1 mg/kg every 30 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol (4 doses of oral alcohol 1 g/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cocaine placebo (4 doses of placebo cocaine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol placebo (4 doses of placebo alcohol)
Number of subjects: 0
Study: 9280322

Group type: EXPERIMENTAL
Intervention: First protocol (2 units of fresh-frozen plasma and one buffy coat-poor RBC concentrate)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Second protocol (additional in-line filtration of RBC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Third protocol (additional platelet concentrate recovery from buffy coat)
Number of subjects: 60
Study: 1945511

Group type: EXPERIMENTAL
Intervention: Cold therapy for 24 hours postoperatively
Number of subjects: 100

Group type: COMPARATOR
Intervention: No cold therapy
Number of subjects: 100
Study: 7139705

Group type: EXPERIMENTAL
Intervention: Percutaneous insertion of intra-aortic balloon assist
Number of subjects: 53

Group type: COMPARATOR
Intervention: Surgical insertion of intra-aortic balloon assist
Number of subjects: 53
Study: 29959661

Group type: EXPERIMENTAL
Intervention: Offspring of mothers diagnosed with major depression
Number of subjects: 132

Group type: COMPARATOR
Intervention: Healthy comparison mothers
Number of subjects: 132
Study: 30235685

Group type: EXPERIMENTAL
Intervention: Three-Circle Post Standing Qigong (TCPSQ) intervention for 10 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unaltered lifestyle control group
Number of subjects: 80
Study: 27072903

Group type: EXPERIMENTAL
Intervention: Consolidative autologous stem cell transplant (ASCT)
Number of subjects: 198

Group type: COMPARATOR
Intervention: R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone)
Number of subjects: 198
Study: 24794512

Group type: EXPERIMENTAL
Intervention: rTMS on Brodmann Area 9
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rTMS on Brodmann Area 46
Number of subjects: 15
Study: 22639289

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (IGC) for almost 24 h after PCI (n = 82; glucose, 80‐140 mg/dl)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Conventional glycemic control (CGC; n = 83; glucose, 180‐200 mg/dl)
Number of subjects: 165
Study: 20053938

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMS) including folic acid and 30 mg iron
Number of subjects: 4436

Group type: COMPARATOR
Intervention: Folic acid and 30 mg iron (Fe30Fol)
Number of subjects: 4436

Group type: COMPARATOR
Intervention: Usual food supplementation
Number of subjects: 4436

Group type: EXPERIMENTAL
Intervention: Early food supplementation
Number of subjects: 4436
Study: 18844462

Group type: EXPERIMENTAL
Intervention: Darunavir/r 600/100 mg twice daily
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control protease inhibitors (CPI(s))
Number of subjects: 255
Study: 16496606

Group type: EXPERIMENTAL
Intervention: Patients with CDGD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 20
Study: 12195169

Group type: EXPERIMENTAL
Intervention: Three different hearing aid circuits
Number of subjects: 360
Study: 9924278

Group type: EXPERIMENTAL
Intervention: Breakfast meal (standard energy content)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Breakfast meal (doubled energy content)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fasting trial
Number of subjects: 9
Study: 8171949

Group type: EXPERIMENTAL
Intervention: Fentanyl and vecuronium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hypnotics (etomidate, midazolam, propofol)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Orotracheal intubation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hypnotics
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post intubation period
Number of subjects: 60

Group type: COMPARATOR
Intervention: Various hypnotics
Number of subjects: 60
Study: 2965125

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 12
Study: 30273277

Group type: EXPERIMENTAL
Intervention: Positive psychology (PP) intervention
Number of subjects: 10
Study: 27401514

Group type: EXPERIMENTAL
Intervention: Telephone-based symptom management (TSM) consisting of cognitive-behavioral and emotion-focused therapy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Telephone-based symptom management (TSM)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Education/support condition
Number of subjects: 106
Study: 25146070

Group type: EXPERIMENTAL
Intervention: Spa adjuvant therapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control
Number of subjects: 128
Study: 22741257

Group type: EXPERIMENTAL
Intervention: Surrounding needling of electroacupuncture and hot compress of Chinese medicine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional needling method and local cupping
Number of subjects: 86
Study: 19783466

Group type: EXPERIMENTAL
Intervention: Acuvue Oasys for Astigmatism (AOfA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Purevision Toric (PVT)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Air Optix for Astigmatism (AOT)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Proclear Toric (PCT)
Number of subjects: 14
Study: 19027437

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation Training (PMR)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control (sham therapy or wait-list)
Number of subjects: 155
Study: 16050413

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcimimetics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatments with selective drugs
Number of subjects: 0
Study: 12871555

Group type: EXPERIMENTAL
Intervention: Vitamin C treatment (1 g day‐1 for 5 days)
Number of subjects: 61
Study: 10591711

Group type: EXPERIMENTAL
Intervention: Hypericum extract (1050 mg, 350 mg three times daily)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Imipramine (100 mg, 50 mg, 25 mg, and 25 mg daily)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Hypericum extract
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 263
Study: 8910180

Group type: EXPERIMENTAL
Intervention: Lidocaine 10 mg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lidocaine 30 mg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (no lidocaine)
Number of subjects: 135
Study: 1283888

Group type: EXPERIMENTAL
Intervention: Mexiletine (300 mg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Disopyramide (300 mg/day)
Number of subjects: 44
Study: 6371627

Group type: EXPERIMENTAL
Intervention: melphalan and 5‐fluorouracil daily for four days, repeated every four weeks with megace daily for eight weeks
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: adriamycin, 5‐fluorouracil, and cyclophosphamide, intravenous bolus every 21 days with megace daily for eight weeks
Number of subjects: 358

Group type: COMPARATOR
Intervention: Control group (63 patients with known cardiac disease assigned to regimen 1)
Number of subjects: 358
Study: 30882856

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0
Study: 30235437

Group type: EXPERIMENTAL
Intervention: N2O/O2
Number of subjects: 33

Group type: COMPARATOR
Intervention: O2
Number of subjects: 33
Study: 27329612

Group type: EXPERIMENTAL
Intervention: 600 ml of fructose beverage
Number of subjects: 41

Group type: COMPARATOR
Intervention: 600 ml of glucose beverage (control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 600 ml of soft drink
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 355 ml of soft drink
Number of subjects: 41
Study: 25007689

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 microg plus 3 ml of 0.5% hyperbaric bupivacaine (Group BF)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Normal saline plus 3 ml of 0.5% hyperbaric bupivacaine (Group BS)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Intrathecal tramadol 25 mg plus 3 ml of 0.5% hyperbaric bupivacaine (Group BT)
Number of subjects: 186
Study: 22289106

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 30
Study: 20466294

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 240

Group type: COMPARATOR
Intervention: PGE(2)
Number of subjects: 240
Study: 17389213

Group type: COMPARATOR
Intervention: Stented bioprostheses (Carpentier‐Edwards Perimount [CEP])
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Stentless bioprostheses (Toronto SPV)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Stentless bioprostheses (Shelhigh Super Stentless)
Number of subjects: 68
Study: 16218010

Group type: EXPERIMENTAL
Intervention: Restorative intervention using the natural environment
Number of subjects: 32
Study: 11863352

Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 19

Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 19
Study: 10418894

Group type: EXPERIMENTAL
Intervention: Simultaneously administered influenza and pneumococcal vaccines
Number of subjects: 26925

Group type: COMPARATOR
Intervention: Influenza vaccine alone
Number of subjects: 26925
Study: 7594124

Group type: EXPERIMENTAL
Intervention: High-Ca group (1,400 mg Ca per day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low-Ca group (400 mg Ca per day)
Number of subjects: 11
Study: 2141886

Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate
Number of subjects: 10
Study: 6456202

Group type: EXPERIMENTAL
Intervention: 20 mg metoclopramide
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 31412087

Group type: EXPERIMENTAL
Intervention: Recombinant BGL2 (rBGL2ur) antigen
Number of subjects: 90

Group type: COMPARATOR
Intervention: Proprietary MiraVista Diagnostic (MVD) IgM
Number of subjects: 90

Group type: COMPARATOR
Intervention: ID-TP assay using non-concentrated patient sera
Number of subjects: 90
Study: 28619020

Group type: EXPERIMENTAL
Intervention: Cross-year peer tutoring (CYPT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Faculty-led training (FLT)
Number of subjects: 116
Study: 23800161

Group type: EXPERIMENTAL
Intervention: 40 mg injection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 40 mg infusion every 12 h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 40 mg infusion followed by continuous infusion at 8 mg/h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 80 mg infusion followed by continuous infusion at 4 or 8 mg/h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Continuous infusion
Number of subjects: 20
Study: 21670453

Group type: EXPERIMENTAL
Intervention: Palifermin (180 μg/kg) administered before chemoradiotherapy and once weekly for 7 weeks
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 19194993

Group type: EXPERIMENTAL
Intervention: Communication skills training (CS training)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no CS training)
Number of subjects: 89
Study: 17023233

Group type: EXPERIMENTAL
Intervention: Carvedilol IR (Immediate-Release)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carvedilol CR (Controlled-Release)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol IR and Carvedilol CR
Number of subjects: 0
Study: 15250016

Group type: COMPARATOR
Intervention: Cefepime monotherapy
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Cefepime/amikacin combination (dual) therapy
Number of subjects: 189
Study: 11745911

Group type: EXPERIMENTAL
Intervention: Linezolid tablets administered while fasting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linezolid tablets administered after a high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 375-mg oral dose of linezolid (tablets) while fasting
Number of subjects: 0

Group type: COMPARATOR
Intervention: 375-mg intravenous linezolid solution
Number of subjects: 0
Study: 9417761

Group type: EXPERIMENTAL
Intervention: Injection of rhenium‐186 combined with triamcinolonhexacetonid (group 1)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Injection of triamcinolonhexacetonid alone (group 2)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Injection of erbium‐169 combined with triamcinolonhexacetonid (group 3)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Injection of triamcinolonhexacetonid alone (group 4)
Number of subjects: 228
Study: 8518353

Group type: EXPERIMENTAL
Intervention: Diet A (dietary advice)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet B (low calorie daily menus)
Number of subjects: 0
Study: 2979677

Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10
Study: 31122843

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided erector spinae plane block (ESPB) administered preoperatively
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 29960767

Group type: EXPERIMENTAL
Intervention: 25 minitablets
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: 100 minitablets
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: 400 minitablets
Number of subjects: 372

Group type: COMPARATOR
Intervention: 5 mL syrup
Number of subjects: 372

Group type: COMPARATOR
Intervention: 10 mL syrup
Number of subjects: 372
Study: 26929280

Group type: EXPERIMENTAL
Intervention: Ultrapro mesh (pore size 3-4 mm)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Optilene LP mesh (pore size 1 mm)
Number of subjects: 128
Study: 25222607

Group type: EXPERIMENTAL
Intervention: Val158 variant during medication and placebo treatment
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Val158/Val158 carriers
Number of subjects: 62
Study: 23176879

Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg or 20 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Salbutamol (5 mg nebulized)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Spirometry
Number of subjects: 13